Ann: Annual Report to Shareholders, page-40

You guys do a good job keeping me interested. I also agree that Roth Capital will do a good job for them with the listing on NASDAQ (and they will be loaded to the 'tits' as you like to describe it). IHL will have cash after listing. ... But how the SP will perform can / could be another story.

So, I had a look at Roth Capital's website and the healthcare deals they are showcasing there as their deals:

• Unicycive (minus 53% YTD performance)
• TFF (minus 43% YTD performance)
• Kempharm (minus 18% YTD performance)
• AppliedDNASciences (plus 12% YTD performance)
• Immunic Therapeutics (minus 35% YTD performance)
• Delcath Systems (minus 41% YTD performance)
• Cyclacel (minus 24% YTD performance)

Of course it is possible to pick other time frames than 'year to date' to make things look different or better, but I just kept the same for everyone. For comparison: NASDAQ composite is plus 21% year to date.

So, now, I have two options:

1. Buy now and sell reasonably quickly after listing; otherwise my chances are 1 out of 7; ... so no long term investment
2. Watch on: no pain ... and no gain

... scratching my head ...